CELU Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Celularity Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerCELU

Market Cap29.8M

Cash RunwayRunway < 6 months

Next Catalystn/a

Public Research Snapshot

Celularity Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for PDA-002 in Diabetic Foot Ulcers Complicated by Peripheral Artery Disease (Phase 2).

Pipeline

Asset	Indication	Modality	Stage	Public Note
PDA-002	Diabetic Foot Ulcers Complicated by Peripheral Artery Disease	n/a	Phase 2	Public pipeline row
EOP-2	n/a	n/a	Phase 2	Public pipeline row
CD19	n/a	n/a	Preclinical	Public pipeline row
RESOURCES	n/a	n/a	n/a	Public pipeline row
CYNK-001	n/a	Cell Therapy	Preclinical	Public pipeline row
COVID-19	n/a	n/a	n/a	Public pipeline row
CYNK-101	n/a	Antibody	Preclinical	Public pipeline row
CD34	n/a	Cell Therapy	Phase 1	Public pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT01261403	Phase 2	TERMINATED	26	2012-02
NCT02515786	Phase 1 \| Phase 2	UNKNOWN	19	2015-07
NCT02136550	Na	UNKNOWN	36	2015-12
NCT02552277	Phase 2	COMPLETED	26	2017-03-07
NCT02264288	Phase 2	TERMINATED	159	2018-02-28
NCT04489420	Phase 1	TERMINATED	3	2021-08-10
NCT04797728	Early_Phase 1	COMPLETED	23	2022-02-08
NCT04310592	Phase 1	TERMINATED	27	2023-01-20

Scientific Context

clinical_stage | Phase 1 | Phase 2
clinical_stage | Phase 1 | Phase 2
indication | Astrocytoma, Grade IV | Glioblastoma | Giant Cell Glioblastoma | Glioblastoma Multiforme
indication | Astrocytoma, Grade IV | Glioblastoma | Giant Cell Glioblastoma | Glioblastoma Multiforme
asset_name | 3 x 10^6 cells

Want the full CELU research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.